Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Chronic inflammatory demyelinating polyneuropathy (CIDP), also called chronic relapsing polyneuropathy, is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. Symptoms include initial limb weakness, both proximal and distal, orthostatic dizziness, tingling, and numbness of hands and feet.

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development market research report provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and features dormant and discontinued projects.

CIDP Pipeline Drugs Market Targets

The targets of the CIDP pipeline drugs market are IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Complement C1s Subcomponent, Envelope Protein, and T Cell Surface Glycoprotein CD4.

CIDP pipeline drugs market, by targets

CIDP pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of CIDP Pipeline Drugs Market

The mechanisms of action of the CIDP pipeline drugs market are IgG Receptor FcRn Large Subunit p51 Antagonist, Complement C1s Subcomponent Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, and T Cell Surface Glycoprotein CD4 Inhibitor.

CIDP pipeline drugs market, by mechanisms of action

CIDP pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in CIDP Pipeline Drugs Market

The routes of administration in the CIDP pipeline drugs market are intravenous, subcutaneous, and parenteral.

CIDP pipeline drugs market, by routes of administration

CIDP pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in CIDP Pipeline Drugs Market

The molecule types in the CIDP pipeline drugs market are monoclonal antibody, antibody, cell therapy, fusion protein, recombinant enzyme, and synthetic peptide.

CIDP pipeline drugs market, by molecule types

CIDP pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key CIDP Pipeline Drugs Market Companies

Some of the key companies in the CIDP pipeline drugs market are Argenx SE, Octapharma AG, Takeda Pharmaceutical Co Ltd, Biogen Inc, Cellenkos Inc, GeNeuro SA, HanAll Biopharma Co Ltd, Immupharma Plc, Johnson & Johnson, and Pfizer Inc.

CIDP pipeline drugs market, by key companies

CIDP pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets IgG Receptor FcRn Large Subunit p51, Cells Expressing B Lymphocyte Antigen CD20, Complement C1s Subcomponent, Envelope Protein, and T Cell Surface Glycoprotein CD4
Mechanisms of Action IgG Receptor FcRn Large Subunit p51 Antagonist, Complement C1s Subcomponent Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, and T Cell Surface Glycoprotein CD4 Inhibitor
Routes of Administration Intravenous, Subcutaneous, and Parenteral
Molecule Types Monoclonal Antibody, Antibody, Cell Therapy, Fusion Protein, Recombinant Enzyme, and Synthetic Peptide
Key Companies Argenx SE, Octapharma AG, Takeda Pharmaceutical Co Ltd, Biogen Inc, Cellenkos Inc, GeNeuro SA, HanAll Biopharma Co Ltd, Immupharma Plc, Johnson & Johnson, and Pfizer Inc

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
  • Reviews of pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • Evaluation of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Overview

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Companies Involved in Therapeutics Development

Argenx SE

Biogen Inc

Cellenkos Inc

GeNeuro SA

HanAll Biopharma Co Ltd

Immupharma Plc

Johnson & Johnson

Octapharma AG

Pfizer Inc

Sanofi

Takeda Pharmaceutical Co Ltd

UCB SA

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Drug Profiles

batoclimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

CK-0803 – Drug Profile

Product Description

Mechanism Of Action

History of Events

efgartigimod alfa – Drug Profile

Product Description

Mechanism Of Action

History of Events

forigerimod acetate – Drug Profile

Product Description

Mechanism Of Action

History of Events

hyaluronidase (recombinant, human) + immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

immune globulin (human) – Drug Profile

Product Description

Mechanism Of Action

History of Events

M-254 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PF-06755347 – Drug Profile

Product Description

Mechanism Of Action

History of Events

rituximab – Drug Profile

Product Description

Mechanism Of Action

History of Events

rozanolixizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

SAR-445088 – Drug Profile

Product Description

Mechanism Of Action

History of Events

temelimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Dormant Projects

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Discontinued Products

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Product Development Milestones

Featured News & Press Releases

Nov 16, 2021: Zai Lab announces first patient dosed in greater China in global registrational clinical trial of efgartigimod in CIDP

Oct 08, 2021: argenx to highlight potential first-in-class FcRn antagonist Efgartigimod at upcoming Neuromuscular Meetings

Sep 01, 2021: Harbour BioMed announces IND approval for phase II trial of Anti-FcRn Batoclimab in chronic inflammatory demyelinating polyneuropathy in China

Feb 12, 2021: U.S. FDA approves PANZYGA for the treatment of adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Feb 02, 2021: argenx issues statement concerning Efgartigimod

Feb 01, 2021: Argenx announces “GO” decision in adhere trial of Efgartigimod in chronic inflammatory demyelinating polyneuropathy following interim analysis

May 18, 2020: Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga (NewGam) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) presented at AAN 2020

Feb 19, 2019: Gliknik to receive $15 million milestone payment from Pfizer following clinical progress with PF-06755347, previously known as GL-2045

Jun 14, 2018: ImmuPharma: Results of CIDP Pre-Clinical Data

Feb 22, 2018: GeNeuro receives Orphan Drug Designation from the US FDA for GNbAC1 in chronic inflammatory demyelinating polyneuropathy (CIDP)

Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Argenx SE, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Biogen Inc, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Cellenkos Inc, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by GeNeuro SA, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by HanAll Biopharma Co Ltd, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Immupharma Plc, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Johnson & Johnson, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Octapharma AG, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Pfizer Inc, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Sanofi, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by Takeda Pharmaceutical Co Ltd, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Pipeline by UCB SA, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Dormant Projects, 2022

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.